An exploratory, open‐label, investigator‐initiated study of interleukin‐17 blockade in patients with moderate‐to‐severe papulopustular rosacea

Abstract

Currently, few systemic medications are effective for rosacea.¹ Recent research has shown elevation of interleukin (IL)‐17A in rosacea.^2,3 To assess if the IL‐17A inhibitor,^{4, 5} secukinumab, could improve moderate to severe papulopustular rosacea (PPR), an exploratory, open‐label, single‐arm investigator initiated clinical trial in adults with moderate to severe PPR was performed after Stanford Human Subjects Panel approval.